AbbVie Finalizes Landos Biopharma Acquisition

AbbVie Inc., a global biopharmaceutical company, has completed the acquisition of Landos Biopharma Inc., integrating Landos into its operations. This strategic move brings NX-13, Landos' lead investigational asset, under AbbVie's extensive immunology pipeline, with potential implications for treating ulcerative colitis (UC) and Crohn's disease (CD).

NX-13: A Promising New Treatment

NX-13 is an innovative, oral NLRX1 agonist, a first-in-class drug within the NOD-like receptor family. Currently undergoing Phase 2 clinical trials, NX-13 is being tested for its effectiveness in moderate to severe UC cases. The NLRX1 receptor plays a crucial role in regulating immunometabolism and inflammation, and its activation by NX-13 could provide a novel therapeutic pathway for inflammatory bowel diseases (IBD).

The dual mechanism of NX-13 not only reduces inflammation but also aids in epithelial repair, making it a promising candidate for addressing the underlying pathogenesis of UC and CD. "Many individuals with IBD struggle to maintain remission and continue to suffer from severe symptoms," stated Kori Wallace, M.D., Ph.D., vice president and global head of immunology clinical development at AbbVie. Wallace underscored that NX-13 complements AbbVie’s existing immunology portfolio and reinforces their commitment to transforming the standard of care for such conditions.

Financial Details of the Acquisition

AbbVie acquired Landos Biopharma at a rate of $20.42 per share, along with a contingent value right per share worth up to $11.14, contingent on achieving specific clinical development milestones. As a result, Landos’ common stock will be removed from the NASDAQ stock exchange before the market opens on May 24, 2024.

NEXUS Study: Evaluating NX-13

The NEXUS study is a Phase 2 proof-of-concept clinical trial assessing NX-13’s efficacy in patients with moderate to severe UC. This trial is a randomized, multicenter, double-blind, placebo-controlled study involving multiple doses over a 12-week induction period. The study includes 80 participants with moderate to severe UC, with a long-term extension phase for further evaluation. Participants are randomized to receive either 250 mg or 750 mg of immediate-release NX-13 or a placebo. The primary aim of this trial is to evaluate the clinical efficacy, safety, and pharmacokinetics of NX-13 compared to a placebo.

About AbbVie

AbbVie is dedicated to discovering and delivering innovative medicines to address serious health issues and future medical challenges. The company focuses on several key therapeutic areas including immunology, oncology, neuroscience, and eye care. AbbVie also offers products and services in its Allergan Aesthetics portfolio.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!